Constipation is more common in those whose guts contain larger concentrations of archaea, a kind of methane-producing microbe, according to a study published in the journal Clinical Gastroenterology and Hepatology. This finding may result in more focused therapies for this prevalent gastrointestinal problem. After analysing data from more than 1,500 people, researchers at Cedars-Sinai Medical Centre discovered that people with intestinal methanogen overgrowth (IMO) were more likely to have symptoms like bloating, stomach pain, and trouble passing gas.

“Our study found that patients with IMO are more likely to have constipation, particularly severe constipation, and less likely to have unyielding diarrhoea,” said the study’s corresponding author, Ali Rezaie, MD, medical director of the Cedars-Sinai GI Motility Program and director of Bioinformatics at the Medically Associated Science and Technology (MAST) program at Cedars-Sinai. “Patients, however, also reported several other gut-related symptoms, including bloating, diarrhoea, abdominal pain, and flatulence.”

As per a release by Cedars-Sinai Medical Centre, constipation is one of the most common gut-related issues in the United States. About 16% of adults experience bloating, abdominal pain, and difficulty having bowel movements; the numbers nearly double for people over 60. While many things, like medication side effects or lack of dietary fibre, can cause constipation, historically, there has been a shortage of research on the gut microbiome’s role in constipation and other digestive issues.

A simple breath test can be used to diagnose IMO. Patients with excessive methane levels in their breath may benefit from a combination of antibiotics and a specialised diet to suppress the growth of archaea in the gut.

“When there is an excessive amount of archaea in your gut, they produce more methane, and some of that methane makes its way to your bloodstream, then to your lungs, and you breathe it out, where it can be measured as a diagnostic test,” Rezaie said. “Essentially, people who have excessive amounts of methane have a lot of GI symptoms, including constipation, flatulence, bloating, and diarrhoea.”

This research offers hope for people struggling with constipation and paves the way for research exploring the connection between the gut microbiome and digestive health.

A bottle of Ranbaxy Laboratories Ltd.’s atorvastatin calcium tablets arranged for a photograph, February 20, 2014.
| Photo Credit: Dhiraj Singh/Bloomberg

Administering ursodeoxycholic acid (UDCA) can stave off the tendency of statins to induce glucose intolerance and diabetes, a study by a group of researchers in China has found.

(For top health news of the day, subscribe to our newsletter Health Matters)

Statins are prescribed to people with a high risk of cardiovascular disease. They work by blocking the activity of an enzyme involved in the metabolic pathway that produces LDL, or “bad”, cholesterol. Statins are on the World Health Organisation’s list of essential medicines and among the most sold drugs worldwide.

However, many studies have found statins could increase the risk of developing diabetes. “It has been known for a few years now that statins can induce glucose intolerance and even frank diabetes in some people,” V. Mohan, chairman of the Madras Diabetes Research Foundation, said over phone to The Hindu.

He added that doctors have continued to prescribe them because statins’ benefits “far outweigh the risk”.

Nonetheless, the mechanism by which statins have this effect has been unclear.

In the study, published in the February edition of Cell Metabolism, the researchers reported one mechanism through which statins could increase glucose intolerance, involving UDCA, a bile acid.

The team recruited 30 people with atorvastatin and 10 without and tracked their metabolism for four months. They reported that the faeces of those taking atorvastatin had a reduced abundance of bacteria of the genus Clostridium and that these individuals had “altered serum and faecal bile acid profiles” as well.

The gut microbiome is a community of bacteria in the gut in a symbiotic relationship with the body. The researchers found that the Clostridium-deficient microbiome inhibited enzymes called hydroxysteroid dehydrogenases and lowered UDCA.

They also verified an idea that “the decreased Clostridium-rich microbiota might influence bile acid synthesis and excretion and impair glucose metabolism” in a 12-week study of mice.

To check the role of UDCA, they recruited five participants on statins and administered 10-13 mg/kg (of body weight) of UDCA per day. After two months, they found the individuals’ HbA1C levels, among others, were “substantially decreased”.

They concluded that “UDCA restored impaired glucose homeostasis without limiting the lipid-lowering effect of statin”.

Dr. Mohan called the finding “good news” and “a new angle” but also said the underlying hypothesis will have to be tested in randomised clinical trials.

“You are more microbes than human.”

It is possible you have had this factoid thrown at you, with the thrower claiming that the microbes in our bodies outnumber our own cells 10 to one.

But according to an assessment published in Nature Microbiology, this is a myth. In a 2016 study the assessment’s authors cited, researchers from Israel and Canada estimated a 70 kg “reference man” to have 38 trillion bacterial cells and 30 trillion human cells. Most current estimates of the size of the gut microbiome are also based on adults living in the urban areas of high-income countries, they added.

The authors, Alan Walker, senior research fellow at the Rowett Institute, University of Aberdeen, and Lesly Hoyles, professor of microbiome and systems biology, Nottingham Trent University, poked holes into this and 11 other popular claims that assail the human microbiome – the community of microbes living in the human body.

In the last two decades, microbiome research has gone from a “niche subject area” to “one of the hottest topics in all of science,” Dr. Hoyles said. The flip side of this is “hype and a temptation to over-simplify the really complex microbial interactions and activities occurring in our guts”.

Varun Aggarwala, assistant professor of biomedical and life sciences at Jio Institute, Navi Mumbai, who studies microbiome therapeutics, described the assessment as a “timely intervention that can bring nuance to the field of microbiomes.”

Here are the 11 other claims the article checked:

1. The age of the field

One of the more benign misconceptions the assessment takes aim at is that microbiome research is a new field. But according to the authors, scientists had described bacteria inhabiting the gut, such as Escerichia coli and Bifidobacteria, and speculated on their benefits in the late 19th and early 20th centuries itself.

2. Who named the field?

Many have credited Joshua Lederberg, a medicine Nobel laureate, with naming the field in 2001. But researchers had used the term in its modern form more than a decade earlier. According to a June 2017 paper that the authors cite, Whipps J.M., Lewis K., and Cooke R.C. used the term in 1988 to describe a community of microbes in a book.

3. The real number of microbes

Some of the more prevalent and more harmful myths concern the size of the microbiome. The absolute microbial cell numbers in one gram of human faeces have been exaggerated 10- to 100-fold. The actual number is around 10¹⁰-10¹², according to the authors.

4. The mass of the microbiome

Many research articles have stated that the human microbiota weigh 1-2 kg, but it only weighs about half a kg or less, the authors wrote. The 2016 study by Israeli and Canadian researchers estimated that it weighed about 200 grams.

5. From mother to child

Contrary to some opinions, mothers don’t pass their microbiomes to their children at birth. Some microorganisms are directly transferred during birth but they constitute a small fraction of the human microbiota. A smaller fraction of these microbes also survives and persists through the child’s life. “Every adult ends up with a unique microbiota configuration, even identical twins that are raised in the same household,” the authors noted.

6. Good or bad?

Some researchers have suggested (see here, here, and here, e.g.) that diseases are caused by undesirable interactions between microbial communities and our cells. But the authors wrote that whether a microbe and its metabolite are ‘good’ or ‘bad’ depends on the context. For example, most humans carry a species of bacteria called Clostridium difficile without any diseases for life. It causes problems only in the elderly or in people with compromised immune systems.

They acknowledged that diseases have been correlated with changes in the composition of the microbiome and that such changes could exacerbate some diseases (like inflammatory bowel disease). But they added that it is “extremely difficult” to implicate a specific profile of microbes, or changes to them, in a disease.

7. The firmicutes-bacteroidetes ratio

One myth correlates obesity with the ratio of two phyla of bacteria, firmicutes and bacteroidetes. The problem: the level of phyla is too broad to comment on effects with confidence. A phylum is a group within a kingdom. In the descending order of classifying organisms, a kingdom comprises different phyla; a phylum comprises classes; then there are orders, families, genuses, and, finally, species. Even within a bacterial species, several strains behave differently, causing the host to manifest different clinical symptoms. 

8. Not redundant

Some researchers have swung the other way, claiming that different microbes are actually functionally redundant. But the authors wrote that while different bacteria in the human microbiome perform some common important functions, many functions are the preserve of a few species.

9. Sequencing is not necessarily unbiased

The authors noted that the notion that “sequencing is unbiased” is a misconception – that biases can be introduced at various stages of studies based on the microbes’ genetic material, from collecting samples to storing them, even in the choice of software to analyse sequence data.

10. The standards question

According to the authors, there is a common opinion in microbiome research that researchers need standardised methods so that they can compare the findings of different studies. But the assessment stressed that no methodology is perfect and that adopting one universal methodology would come at the cost of turning a blind eye to the limitations of the chosen method.

11. The culturable microbiome

Is it difficult to grow microbes from the human microbiome in the lab? Yes, many say, but the authors pointed to work in the 1970s when scientists cultured diverse microbiome species from the gut. “So current gaps in culture collections are at least in part attributable to a lack of previous effort rather than an inherent ‘unculturability’,” they noted.

Joel P. Joseph is a freelance science journalist and researcher.